Search Videos by Topic or Participant
Browse by Series:

Role of the Multikinase Inhibitor Regorafenib in mCRC

Panelists Johanna Bendell, MD, Sarah Cannon; Marwan Fakih, MD, City of Hope; Heinz-Josef Lenz, MD, USC; John L. Marshall, MD, Georgetown; Ala
Published: Thursday, May 08, 2014
For High-Definition, Click
The CORRECT trial evaluated the efficacy of the multikinase inhibitor regorafenib versus placebo in patients with metastatic colorectal cancer (mCRC) following progression on standard therapies. The regimen used in the CORRECT trial was regorafenib at 160 mg once daily for 3 weeks followed by 1 week off.

In the study, Alan P. Venook, MD, states that overall survival (OS) was improved by 1.4 months in the regorafenib group compared with placebo. In the study, the median OS was 6.4 months with regorafenib compared with 5.0 months with placebo. Additionally, John L. Marshall, MD, notes that about 40% of patients achieved disease stabilization with regorafenib.

Heinz-Josef Lenz, MD, comments that regorafenib can have toxicities that develop quickly. To avoid these adverse events, Lenz suggests initiating therapy with a reduced dose and then titrating the dose upward. Johanna Bendell, MD, and Venook initiate therapy with 80-mg regorafenib with the intention of increasing the dose. Marwan Fakih, MD, states that over 70% of the patients with mCRC in the CORRECT study who received regorafenib required dose modification.

Lenz and Venook recommend frequent follow-up for patients on regorafenib; Venook sees patients weekly and has a nurse call patients twice weekly. Fakih and Lenz stress the importance of discussing the risks and benefits of therapy with patients before initiating regorafenib.


Slider Left
Slider Right
For High-Definition, Click
The CORRECT trial evaluated the efficacy of the multikinase inhibitor regorafenib versus placebo in patients with metastatic colorectal cancer (mCRC) following progression on standard therapies. The regimen used in the CORRECT trial was regorafenib at 160 mg once daily for 3 weeks followed by 1 week off.

In the study, Alan P. Venook, MD, states that overall survival (OS) was improved by 1.4 months in the regorafenib group compared with placebo. In the study, the median OS was 6.4 months with regorafenib compared with 5.0 months with placebo. Additionally, John L. Marshall, MD, notes that about 40% of patients achieved disease stabilization with regorafenib.

Heinz-Josef Lenz, MD, comments that regorafenib can have toxicities that develop quickly. To avoid these adverse events, Lenz suggests initiating therapy with a reduced dose and then titrating the dose upward. Johanna Bendell, MD, and Venook initiate therapy with 80-mg regorafenib with the intention of increasing the dose. Marwan Fakih, MD, states that over 70% of the patients with mCRC in the CORRECT study who received regorafenib required dose modification.

Lenz and Venook recommend frequent follow-up for patients on regorafenib; Venook sees patients weekly and has a nurse call patients twice weekly. Fakih and Lenz stress the importance of discussing the risks and benefits of therapy with patients before initiating regorafenib.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x